Abstract
Abstract Background: Chemokines and their receptors are known to play an important role in tumor progression, particularly as key mediators of tumor-stroma interactions. Studies have investigated the impact of monocyte chemotactic protein-1 (MCP-1) and CC chemokine receptor 2 (CCR2) polymorphisms on the susceptibility of cancer, but the results remain inconclusive. Methods: We performed a meta-analysis using 20 eligible studies to summarize the data on the association between MCP-1 A2518G and CCR2 V64I polymorphisms and cancer risk. Q-statistics and I2 statistics were calculated to examine heterogeneity, and summary odds ratios (OR) and 95% confidence intervals (95% CI) were calculated using a random effects model. Potential sources of heterogeneity were sought out via stratification and sensitivity analyses, and publication biases were estimated. Results: In overall, MCP-1 and CCR2 polymorphisms showed no significant association with cancer risk (MCP-1 A2518G, GG + GA versus AA: OR = 0.94, 95% CI=0.76, 1.17; CCR2 V64I, AA + AG versus GG: OR= 1.30, 95% CI = 0.86, 1.95). The effect of these polymorphisms was further evaluated in stratification analyses. It was demonstrated that the increased risk of cancer was observed among Asian populations carrying at least one A allele of CCR2 V64I than those with GG homozygotes (AA + AG versus GG: OR=1.80; 95% CI=1.40, 2.33). Conclusions: This meta-analysis demonstrates that gene polymorphism of CCR2 V64I may influence the susceptibility of cancer in Asian populations. Further well-designed studies with large sample size should be conducted. Citation Format: Jeongseon Kim, Young Ae Cho. Association of polymorphisms in MCP-1 and CCR2 genes with the risk of cancer: A meta-analysis. [abstract]. In: Proceedings of the AACR Special Conference on Post-GWAS Horizons in Molecular Epidemiology: Digging Deeper into the Environment; 2012 Nov 11-14; Hollywood, FL. Philadelphia (PA): AACR; Cancer Epidemiol Biomarkers Prev 2012;21(11 Suppl):Abstract nr 18.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
